A reduction-responsive RNAi nanoplatform has been developed to silence both MGLL and CB2 to inhibit the production of FFAs, which promotes the classical activation of TAMs to secrete tumor-killing cytokines, such as TNF-α and IL-12, to exert an inhibitory effect on pancreatic cancer [55]. The gene discussed is CNR2; the disease is neoplasm.